A systematic review and meta-analysis of immune-mediated liver dysfunction in non-small cell lung cancer

Autor: Guofu Lin, Lan-Lan Lin, Fan Yang, Xiang-Qi Chen
Rok vydání: 2020
Předmět:
Zdroj: International immunopharmacology. 83
ISSN: 1878-1705
Popis: Background Immune checkpoint inhibitors (ICIs) have been identified as validated medications in non-small cell lung cancer (NSCLC). However, they are often associated with immune-related adverse events (irAEs) including liver dysfunction. Therefore, we conducted a systematic review of the literature and performed a meta-analysis to ascertain overall incidence and risk of immune mediated liver dysfunction in NSCLC patients. Methods PubMed, the Cochrane Library, Embase and ClinicalTrials.gov ( http://clinicaltrials.gov/ ) were searched from inception to December 2019. Studies regarding all grade (1–5), high grade (3–5) hepatitis and ALT or AST elevation were included. Results A total of 11 clinical trials including 7086 patients were selected for further assessment. The overall incidence of ALT elevation, AST elevation and hepatitis for the application of ICIs was 6.18%, 4.99% and 1.09%, respectively. Compared with chemotherapy group, treatment with ICIs had a significantly higher risk of all grade (RR: 7.27, p = 0.001) and high grade (RR: 6.70, p = 0.003) hepatitis. When ICIs combined with chemotherapy, the relative risk of all grade hepatitis was higher than monotherapy group (RR: 7.89, p = 0.044 vs RR: 6.94, p = 0.008). Conclusion The application of ICIs could result in a higher incidence and relative risk of all grade immune-induced liver dysfunction. Moreover, immunotherapy combined with chemotherapy may also increase relative risk of all grade hepatic AEs when compared with monotherapy. Prompt recognition and proper administration is required for clinicians to prevent potentially hepatic deterioration.
Databáze: OpenAIRE
Externí odkaz: